Dr. David Maron, from Vanderbilt School of Medicine, and co-PI of the NHLBI-funded ISCHEMIA trial, speaks about the current guidelines for stable angina, our reluctance to trust optimal medical therapy alone, and the rationale behind ISCHEMIA at Cardiology Grand Rounds.
Dr. Andrew Wang, professor of medicine at Duke, and valvular heart disease specialist, discusses the trial of MV replacement vs. repair in functional, ischemic MR presented this past week at AHA 2013. Matt Sherwood, DCRI fellow, also asks about future of percutaneous treatment of functional MR.
Dr. Bob Giugliano, senior investigator at TIMI group and associate professor at Harvard, discusses the results and implications of the recently published ENGAGE trial which evaluated edoxaban, the most recent Factor Xa inhibitor to be studied in the US.
Marc Pfeffer, Victor Dzau professor at Harvard Medical School, discusses the results and clinical implications of the TOPCAT trial with Tariq Ahmad, DCRI fellow.
Dr. Schuyler Jones, vascular medicine specialist and interventional cardiologist at Duke, discusses the results of the CORAL trial and ERASE trial with Matthew Sherwood, DCRI fellow.
Dr. Christopher Granger, professor of medicine at Duke and head of the CCU, discusses what the results of 2 therapeutic hypothermia trials mean for clinical practice and MISSION Lifeline initiative’s 5 year data, which he presented at AHA 2013. Matt Sherwood, DCRI fellow, discusses.
Dr. Judith Hochman, Senior Associate Dean of Clinical Sciences at the NYU Langone Medical Center, and Snyder Family Professor discusses NHLBI funded trials and the design and rationale of the ISCHEMIA trial with Matt Sherwood, DCRI fellow.
Sean Pokorney, DCRI fellow discusses transition from fellowship to faculty, and good advice for research fellows with Jeffrey Berger, Assistant Professor at NYU Langone Medical Center.
Dr. Neil Stone, chair of the ATP 4 guidelines committee, discuss the new controversial guidelines, use of the risk calculator, and the use of the guidelines in the future with Sean Pokorney, DCRI fellow.
Adrian Hernandez, Associate professor at Duke, Director of Outcomes Research at DCRI, discusses his role as moderator of the CHF late breaking clinical trials, and his interpretation of ROSE-HF and TOPCAT results with DCRI fellow Prateeti Khazanie.